Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

Published:2016-06 Issue: Volume:60 Page:12-25
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Belum V.R.,Benhuri B.,Postow M.A.,Hellmann M.D.,Lesokhin A.M.,Segal N.H.,Motzer R.J.,Wu S.,Busam K.J.,Wolchok J.D.,Lacouture M.E.

Funder

National Institutes of Health/National Cancer Institute

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference49 articles.

1. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy;Callahan;J Leukoc Biol,2013

2. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation;Freeman;J Exp Med,2000

3. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion;Dong;Nat Med,2002

4. PD-1 and PD-1 ligands: from discovery to clinical application;Okazaki;Int Immunol,2007

5. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells;Francisco;J Exp Med,2009

Cited by 341 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Notfälle in der Medikamentösen Tumortherapie;TumorDiagnostik & Therapie;2024-09

2. The Impact of Immune Checkpoint Inhibitors-Induced Skin Toxicity on Patients’ Quality of Life and the Role of Dermatologic Intervention;Dermatology Practical & Conceptual;2024-07-31

3. Cyclosporine for Recalcitrant Bullous Pemphigoid Induced by Nivolumab Therapy for Malignant Melanoma;Cutis;2024-07-01

4. Characterizing immune checkpoint inhibitor-related cutaneous adverse reactions: A comprehensive analysis of FDA adverse event reporting system (FAERS) database;Heliyon;2024-07

5. Notfälle in der Medikamentösen Tumortherapie;Onkologische Welt;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3